AstraZeneca reports Phase III results for Ultomiris and Sone-Ve
AstraZeneca has released findings from two Phase III studies of Ultomiris (ravulizumab) in thrombotic microangiopathy following haematopoietic stem…
#EuropeSays #Britain #Europe #EU #AstraZeneca #gastriccancer #HSCT-TMA #OrphanDrugDesignation #paediatricpatients #PhaseIII #PhaseIIItrial #primaryendpoint #statisticalsignificance #thromboticmicroangiopathy #Ultomiris
https://www.europesays.com/britain/92171/